Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.45 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.45 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.45 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972687 | 0.92 | GPR27 (0.52) | LMNASMN1; SMN2GPR27KMT2AMEN1 | |
| SCHEMBL491583 | 0.91 | ALDH1A1 (0.55) | LMNASMN1; SMN2GPR27KMT2AMEN1 | |
| SCHEMBL492309 | 0.83 | SLC10A6 (0.61) | LMNASMN1; SMN2GPR27KMT2AMEN1 | |
| SCHEMBL972258 | 0.83 | THRB (0.55) | LMNASMN1; SMN2GPR27KMT2AMEN1 | |
| SCHEMBL491824 | 0.82 | KMT2A (0.49) | LMNASMN1; SMN2GPR27KMT2AMEN1 | |
| SCHEMBL492078 | 0.82 | ALDH1A1 (0.55) | LMNASMN1; SMN2GPR27KMT2AMEN1 | |
| SCHEMBL6862427 | 0.80 | KMT2A (0.58) | GPR27KMT2AMEN1GRM4KDM4E | |
| SCHEMBL491092 | 0.80 | SLC10A2 (0.57) | LMNASMN1; SMN2GPR27KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL971595 | 0.79 | SLC10A2 (0.56) | LMNASMN1; SMN2GPR27KMT2AMEN1 | |
| SCHEMBL29382580 | 0.79 | ALDH1A1 (0.59) | LMNASMN1; SMN2GPR27KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207541-B1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8518998-B2 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| CN-101815514-B | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI AVENTIS DEUTSCHLAND | 2012-05-09 | — | — | CN | disclosed |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| CN-101815514-A | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI AVENTIS DEUTSCHLAND | 2010-08-25 | — | — | CN | disclosed |
| EP-2207541-A1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | Sanofi-Aventis Deutschland GmbH (DE) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009043495-A1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SCN1A, SCN2A, CACNA1A | LMNA 2591/4885SMN1; SMN2 157/4885GPR27 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.